Abstract
Background
Data on the current estimates of the disease burden of Clostridioides difficile (C. difficile) infection in the setting of end-stage liver disease (ESLD) are emerging.
Aims
We examined the recent trends and predictors of hospitalizations and in-hospital mortality from C. difficile infection among hospitalizations with ESLD in the USA.
Methods
We performed a retrospective analysis using the National Inpatient Sample, 2005–2014. We defined ESLD and C. difficile infection using the International Classification of Diseases, Ninth Revision, Clinical Modification. Multivariable logistic regression was used to determine the risk factors that impacted hospitalization and mortality.
Results
The prevalence of coding for C. difficile infection in decompensated cirrhosis increased from 1.3% in 2005 to 2.7% in 2014, with an annual rate of 7.8%. In hospitalizations with hepatocellular carcinoma, C. difficile infection increased steadily from 1.0 to 1.7% with an annual incremental rate of 6.4%. Among hospitalizations with ESLD, each passing 2-year period, increasing age, female, higher Charlson index, accompanying infection, hepatorenal syndrome, and ascites were associated with C. difficile infection. Although C. difficile infection was an independent predictor of in-hospital mortality during hospitalization with decompensated cirrhosis (odds ratio 1.53, 95% confidence interval 1.44–1.63), the proportion of in-hospital mortality during hospitalization with C. difficile infection and decompensated cirrhosis decreased from 15.4% in 2005 to 11.1% in 2014, with an annual rate of − 3.1% (95% CI − 5.7% to − 0.3%).
Conclusions
While the prevalence of C. difficile infection in hospitalized patients with ESLD increased approximately twofold, the in-hospital mortality decreased significantly during the past decade.
Similar content being viewed by others
Abbreviations
- ESLD:
-
End-stage liver disease
- HCC:
-
Hepatocellular carcinoma
- NIS:
-
National Inpatient Sample
- ICD-9-CM:
-
International Classification of Diseases, 9th Revision Clinical Modification
- NAFLD:
-
Nonalcoholic fatty liver disease
- APC:
-
Annual percentage change
- CI:
-
Confidence interval
- OR:
-
Odds ratio
References
Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol. 2007;46:827–839.
Mortality GBD. Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171.
Kim D, Cholankeril G, Li AA, et al. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005–2014. Liver Int. 2019;39:1661–1671.
Kim D, Li AA, Perumpail BJ, et al. Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology. 2019;69:1064–1074.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(1264–1273):e1261.
Kim D, Li AA, Gadiparthi C, et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology.. 2018;155:1154–1163.
Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498. (quiz 499).
Ziakas PD, Zacharioudakis IM, Zervou FN, Grigoras C, Pliakos EE, Mylonakis E. Asymptomatic carriers of toxigenic C. difficile in long-term care facilities: a meta-analysis of prevalence and risk factors. PLoS ONE. 2015;10:e0117195.
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–834.
Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208.
Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–92.
Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol. 2010;105:106–113.
Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther. 2014;40:105–112.
Project HCaU. National Inpatient Sample. Agency for Healthcare Research and Quality. https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed Aug 8, 2018.
Schmidt ML, Barritt AS, Orman ES, Hayashi PH. Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology. 2015;148(967–977):e962.
Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of Hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(1090–1099):e1091.
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730.
Dubberke ER, Butler AM, Nyazee HA, et al. The impact of ICD-9-CM code rank order on the estimated prevalence of Clostridium difficile infections. Clin Infect Dis. 2011;53:20–25.
Quality AfHRa. Medical Expenditure Panel Survey: using appropriate price indices for analyses ofhealth care expenditures or income across multiple years. https://meps.ahrq.gov/about_meps/Price_Index.shtml. Accessed Aug 2018.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–351.
Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309–318.
Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
Garcia-Tsao G, Surawicz CM. Editorial: Clostridium difficile infection: yet another predictor of poor outcome in cirrhosis. Am J Gastroenterol. 2010;105:114–116.
Microbiology. ASf. A Practical Guidance Document for the Laboratory Detection of Toxigenic Clostridium difficile. Available at: https://apic.org/Resource_/TinyMceFileManager/Practice_Guidance/cdiff/ASM_Guidance_for_Laboratory_Detection.pdf. Accessed November 2019. 2010.
Cohen J, Limbago B, Dumyati G, et al. Impact of changes in Clostridium difficile testing practices on stool rejection policies and C. difficile positivity rates across multiple laboratories in the United States. J Clin Microbiol. 2014;52:632–634.
Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–2995.
Dubberke ER, Reske KA, McDonald LC, Fraser VJ. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis. 2006;12:1576–1579.
Funding
None.
Author information
Authors and Affiliations
Contributions
DK developed the study concept and design and was involved in acquisition, analysis, and interpretation of data. He developed the manuscript outline, obtained input from co-authors and drafted the manuscript. ERY, AAL, SPT, and GC were involved in interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. AA was involved in developing the study concept and design, analysis, and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and study supervision.
Corresponding author
Ethics declarations
Conflict of interest
Nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kim, D., Yoo, E.R., Li, A.A. et al. Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005–2014. Dig Dis Sci 66, 296–307 (2021). https://doi.org/10.1007/s10620-020-06162-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-020-06162-0